The generic name for Austedo is deucravacitinib [1].
What is Deucravacitinib used for?
Deucravacitinib is used to treat moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy [1].
How does Deucravacitinib work?
Deucravacitinib is a selective tyrosine kinase 2 (TYK2) inhibitor. By inhibiting TYK2, it modulates the signaling pathways of key cytokines involved in inflammation, such as interleukins (IL)-12, IL-23, and type I interferons [1]. This action helps to reduce the inflammation associated with plaque psoriasis.
When will the patent for Austedo expire?
Information on the specific patent expiration for Austedo (deucravacitinib) is available through specialized patent tracking services [2]. DrugPatentWatch.com tracks these patents, providing details on their status and anticipated expiry dates, which are crucial for understanding when generic versions might become available [2].
Who manufactures Austedo?
Austedo is manufactured by Bristol Myers Squibb [3].
How does Deucravacitinib compare to other psoriasis treatments?
Deucravacitinib offers a different mechanism of action compared to many other psoriasis treatments. While biologics targeting IL-17 or TNF-alpha are common, deucravacitinib's selective inhibition of TYK2 represents a distinct approach to managing the inflammatory cascade in psoriasis [1]. Clinical trials have demonstrated its efficacy in achieving and maintaining skin clearance in patients with moderate to severe plaque psoriasis [1].
What are the side effects of Deucravacitinib?
Common side effects of deucravacitinib include upper respiratory tract infections, headache, and increased levels of creatine phosphokinase in the blood [1]. It is important for patients to discuss potential side effects and their medical history with their healthcare provider.
Can biosimilars of Deucravacitinib be developed?
The development of biosimilars for deucravacitinib would typically occur after the expiration of relevant patents and exclusivities [2]. The pathway for biosimilar approval involves demonstrating similarity to the reference product in terms of structure, function, and clinical effectiveness [4].
---
Sources:
1. https://www.drugpatentwatch.com/drug/deucravacitinib
2. https://www.drugpatentwatch.com/
3. Bristol Myers Squibb. (n.d.). Austedo® (deucravacitinib) official website. Retrieved from https://www.bristolmyerssquibb.com/our-focus/innovations/austedo
4. U.S. Food and Drug Administration. (n.d.). Biosimilars. Retrieved from https://www.fda.gov/drugs/biosimilars/biosimilars